Patent · US Expired

Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines

US6147089A · kind A · utility

35Cited by
5References
34Claims
0Family size

Assignee

Inventors

Key dates

Filing dateSep 7, 1999
Grant dateNov 14, 2000
Priority date
Expiry dateSep 7, 2019

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY02P20/55
  • WIPO fieldOrganic fine chemistry
  • WIPO sectorChemistry

Abstract

Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.